AR035806A1 - Formulacion farmaceutica de liberacion inmediata apropiada para compuestos antiarritmicos, procedimiento para su preparacion, composicion farmaceutica solida, composicion liofilizada, uso de la formulacion o la composicion para la manufactura de un medicamento para ser usado en la profilaxis o trata - Google Patents

Formulacion farmaceutica de liberacion inmediata apropiada para compuestos antiarritmicos, procedimiento para su preparacion, composicion farmaceutica solida, composicion liofilizada, uso de la formulacion o la composicion para la manufactura de un medicamento para ser usado en la profilaxis o trata

Info

Publication number
AR035806A1
AR035806A1 ARP020101187A ARP020101187A AR035806A1 AR 035806 A1 AR035806 A1 AR 035806A1 AR P020101187 A ARP020101187 A AR P020101187A AR P020101187 A ARP020101187 A AR P020101187A AR 035806 A1 AR035806 A1 AR 035806A1
Authority
AR
Argentina
Prior art keywords
composition
formulation
compounds
manufacture
preparation
Prior art date
Application number
ARP020101187A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR035806A1 publication Critical patent/AR035806A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Formulaciones farmacéuticas de liberación inmediata particularmente apropiadas para uso parenteral que comprenden como ingrediente activo 4-({3-[´7-(3,3-dimetil-2-oxobutil)-9-oxa-3,7-diazabiciclo-[3.3.1] non-3-il]propil}amino)benzonitrilo, 2-{7-[3-(4-cianoanilino)propil]-9-oxa-3,7-diazabiciclo[3.3.1]non-3-il}etilcarbamato de ter-butilo, 2-{7[4-(4-cianofenil)butil]-9-oxa-3,7-diazabiciclo[3.3.1]non-3-il}etilcarbamato de ter-butilo o 2{7-[(2S)-3-(4-cianofenoxi)-2-hidroxipropil]-9-oxa-3,7-diazabiciclo[3.3.1}etilcarbamato de ter-butilo, o una sal farmacéuticamente aceptable de cualquiera de estos compuestos, y un diluyente o portador farmacéuticamente aceptable particularmente un portador acuoso. Composiciones farmacéuticas sólidas que comprenden un ingrediente activo previamente mencionado donde dichas composiciones son apropiadas para la preparación de formulaciones farmacéuticas de liberación inmediata, y donde dichas composiciones pueden prepararse por ejemplo, mediante secado por congelación, procedimiento para su preparación y uso de esta composición para la manufactura de un medicamento para uso en la profilaxis o el tratamiento de arritmias cardíacas.
ARP020101187A 2001-04-12 2002-04-02 Formulacion farmaceutica de liberacion inmediata apropiada para compuestos antiarritmicos, procedimiento para su preparacion, composicion farmaceutica solida, composicion liofilizada, uso de la formulacion o la composicion para la manufactura de un medicamento para ser usado en la profilaxis o trata AR035806A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0101329A SE0101329D0 (sv) 2001-04-12 2001-04-12 Pharmaceutical formulation

Publications (1)

Publication Number Publication Date
AR035806A1 true AR035806A1 (es) 2004-07-14

Family

ID=20283785

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020101187A AR035806A1 (es) 2001-04-12 2002-04-02 Formulacion farmaceutica de liberacion inmediata apropiada para compuestos antiarritmicos, procedimiento para su preparacion, composicion farmaceutica solida, composicion liofilizada, uso de la formulacion o la composicion para la manufactura de un medicamento para ser usado en la profilaxis o trata

Country Status (26)

Country Link
US (1) US20050037067A1 (es)
EP (1) EP1389212B1 (es)
JP (1) JP2005500262A (es)
KR (1) KR20030088498A (es)
CN (1) CN1514839A (es)
AR (1) AR035806A1 (es)
AT (1) ATE332902T1 (es)
BG (1) BG108234A (es)
BR (1) BR0208828A (es)
CA (1) CA2443473A1 (es)
CZ (1) CZ20032774A3 (es)
DE (1) DE60213084T2 (es)
EE (1) EE200300495A (es)
HU (1) HUP0303486A3 (es)
IL (1) IL158033A0 (es)
IS (1) IS6989A (es)
MX (1) MXPA03009209A (es)
NO (1) NO20034529L (es)
NZ (1) NZ528561A (es)
PL (1) PL366629A1 (es)
RU (1) RU2003129230A (es)
SE (1) SE0101329D0 (es)
SK (1) SK12562003A3 (es)
TW (1) TWI257391B (es)
WO (1) WO2002083689A1 (es)
ZA (1) ZA200307756B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI259836B (en) * 2001-04-12 2006-08-11 Astrazeneca Ab Modified release formulation suitable for antiarrhythmic compounds
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
GB0523810D0 (en) * 2005-11-23 2006-01-04 Astrazeneca Ab Pharmaceutical compositions
EA015682B1 (ru) * 2005-12-20 2011-10-31 Лек Фармасьютиклз Д.Д. Фармацевтическая композиция
US20080085303A1 (en) * 2006-10-10 2008-04-10 Penwest Pharmaceuticals Co. Robust sustained release formulations of oxymorphone and methods of use thereof
CA2644179C (en) * 2007-11-21 2018-09-25 Pharmascience Inc. Novel pharmaceutical composition comprising a disintegration matrix
DE102008047910A1 (de) 2008-09-19 2010-03-25 Molkerei Meggle Wasserburg Gmbh & Co. Kg Tablettierhilfsstoff auf Laktose- und Cellulosebasis
JP5900702B2 (ja) * 2013-03-29 2016-04-06 アステラス製薬株式会社 経口投与用医薬組成物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3732094A1 (de) * 1987-09-24 1989-04-06 Basf Ag Bispidinderivate als klasse iii-antiarrhythmika
US5110933A (en) * 1989-11-13 1992-05-05 Board Of Regents Of Oklahoma State University Salts of 3-azabicyclo[3.3.1]nonanes as antiarrhythmic agents, and precursors thereof
DE4402933A1 (de) * 1994-02-01 1995-08-03 Kali Chemie Pharma Gmbh Neue 3-Benzoyl-3,7-diazabicyclo[3,3,1] nonan-Verbindungen enthaltende Arzneimittel
SE9704709D0 (sv) * 1997-12-17 1997-12-17 Astra Ab Pharmaceutically active compounds
NZ514477A (en) * 1999-04-09 2003-04-29 Astrazeneca Ab Adamantane derivatives
SE9903759D0 (sv) * 1999-10-18 1999-10-18 Astra Ab Pharmaceutically active compounds
US6500457B1 (en) * 2000-08-14 2002-12-31 Peirce Management, Llc Oral pharmaceutical dosage forms for pulsatile delivery of an antiarrhythmic agent

Also Published As

Publication number Publication date
SE0101329D0 (sv) 2001-04-12
TWI257391B (en) 2006-07-01
CA2443473A1 (en) 2002-10-24
RU2003129230A (ru) 2005-04-10
CN1514839A (zh) 2004-07-21
HUP0303486A3 (en) 2005-04-28
DE60213084T2 (de) 2007-01-11
EP1389212B1 (en) 2006-07-12
DE60213084D1 (de) 2006-08-24
BR0208828A (pt) 2004-03-09
BG108234A (bg) 2005-04-30
HUP0303486A2 (hu) 2004-01-28
IS6989A (is) 2003-10-10
KR20030088498A (ko) 2003-11-19
EE200300495A (et) 2003-12-15
NZ528561A (en) 2005-03-24
JP2005500262A (ja) 2005-01-06
MXPA03009209A (es) 2004-01-29
NO20034529D0 (no) 2003-10-09
WO2002083689A1 (en) 2002-10-24
NO20034529L (no) 2003-12-08
PL366629A1 (en) 2005-02-07
IL158033A0 (en) 2004-03-28
ATE332902T1 (de) 2006-08-15
ZA200307756B (en) 2005-01-03
US20050037067A1 (en) 2005-02-17
SK12562003A3 (sk) 2004-03-02
CZ20032774A3 (cs) 2004-01-14
EP1389212A1 (en) 2004-02-18

Similar Documents

Publication Publication Date Title
ES2593582T3 (es) Formulación de comprimido recubierto y método
BRPI0508579A (pt) composto, composição farmacêutica, e, uso de um composto
BR0317294A (pt) Composto, formulação farmacêutica, uso de um composto, métodos de prevenção e/ou tratamento de condições associadas com a glicogênio sintase quinase-3 e de prevenção e/ou tratamento de doenças, e, uso dos intermediários
EE05191B1 (et) Farmatseutiline kompositsioon, mis sisaldab tolterodiini, ja selle kasutamine
TW200621762A (en) Novel compounds
DK1737459T3 (da) Imidazopyridin og imidazopyrimidinderivater som antibakterielle midler
UY28496A1 (es) Compuestos de bencimidazolona que tienen actividad agonista del receptor 5-ht4
JP2004520290A5 (es)
GB0215844D0 (en) Organic compounds
RU98102398A (ru) Использование ингибиторов cgmp-фосфодиэстеразы для лечения импотенции
SV2008002969A (es) Derivados de pirimidina para el tratamiento del crecimiento celular anormal
SE9904508D0 (sv) New compounds
ES2240033T3 (es) Comprimido matricial que permite la liberacion prolongada de trimetazidina tras su administracion oral.
CO5631443A2 (es) Derivados de 7-aril-3,9-diazabiciclo (3.3.1) non-6-eno y su uso como inhibidores de renina en el tratamiento de enfermedades de hipertension, cardiovasculares o renales
WO2006070325A3 (en) 2,3,4,9-tetrahydro-1h-carbazole derivatives as crth2 receptor antagonists
AR026064A1 (es) Compuestos de oxabispidina, formulacion farmaceutica, uso de estos compuestos para la manufactura de medicamentos, proceso para la preparacion de estos compuestos, e intermediarios.
AR035452A1 (es) Sales farmaceuticamente aceptables de compuestos antiarritmicos, procedimiento para la preparación de estas sales, formulación farmaceutica y el uso de estos compuestos para la manufactura de medicamentos para el uso en la profilaxis o el tratamiento de una arritmia
WO2007071965A3 (en) Antibacterial pyrrolopyridines, pyrrolopyrimidines, and pyrroloazepines
TW200606164A (en) New compounds
AR023966A1 (es) Una composicion farmaceutica para la prevencion y/o el tratamiento de la enfermedad de parkinson y los sintomas concomitantes de la misma, y el uso de unantagonista dual receptor de adenosina a1 a2a para preparar dicha composicion
AR035806A1 (es) Formulacion farmaceutica de liberacion inmediata apropiada para compuestos antiarritmicos, procedimiento para su preparacion, composicion farmaceutica solida, composicion liofilizada, uso de la formulacion o la composicion para la manufactura de un medicamento para ser usado en la profilaxis o trata
KR102051132B1 (ko) 미라베그론 또는 이의 염을 포함하는 방출조절용 약제학적 조성물
BRPI0418742A (pt) métodos de tratamento, prevenção ou controle de uma sìndrome mielodisplásica, de redução ou evitação de um efeito adverso associado com a administração de um segundo ingrediente ativo em um paciente sofrendo de um sìndrome mielodisplásica, composição farmacêutica, forma de dosagem unitária única, e, kit
PE20060533A1 (es) Derivados de dicetopiperazina como antagonistas del receptor de oxitocina
BR0315316A (pt) Métodos de tratar, prevenir ou controlar uma sìndrome mielodisplásica, e de reduzir ou evitar um efeito adverso associado com a administração de um segundo ingrediente ativo em um paciente sofrendo de uma sìndrome mielodisplásica, composição farmacêutica, forma de dosagem unitária, e, kit

Legal Events

Date Code Title Description
FA Abandonment or withdrawal